A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.
|Articles|February 5, 2007
New administration route for MDS therapy
Advertisement
Azacitidine for injection (Vidaza, Pharmion) can now be given intravenously according to the FDA. Instructions for the new route of administration will be added to the prescribing information, which includes the existing subcutaneous route instructions. Now, azacitidine can be infused over 10 to 40 minutes and the dosing will remain the same for both types of administration75 mg/m2 daily, for seven days, every four weeks. Azacitidine is approved for treatment of the five subtypes of myelodysplastic syndromes (MDS).
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
A guide built from conversations with pharmacists on social media and independent pharmacy owners.
Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.
Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.
Atogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.
Chad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.
Data show that commercially and Medicaid-insured children with chronic or immunocompromising conditions incur 2- to 3-fold higher costs.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
3
How the Main Street Pharmacy Access Act Advances Pharmacist Provider Status
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5